Scanbase vs Manus AI

Side-by-side comparison of AI visibility scores, market position, and capabilities

Manus AI leads in AI visibility (63 vs 20)

Scanbase

EmergingHealthcare

General

Computer vision API reading at-home lateral flow test photos for 40+ test types; $3M revenue with 5-person team enabling telehealth result verification for COVID, flu, and STD tests.

AI VisibilityBeta
Overall Score
D20
Category Rank
#1030 of 1158
AI Consensus
58%
Trend
up
Per Platform
ChatGPT
20
Perplexity
20
Gemini
12

About

Scanbase is a healthcare technology company providing a computer vision API that enables medical and consumer health companies to analyze at-home diagnostic test results through smartphone photos — reading lateral flow tests (the strip-based rapid tests used for COVID-19, flu, RSV, strep, pregnancy, and STDs) and returning structured results that can be recorded in health apps, telehealth platforms, and clinical systems. Founded in 2022 in San Francisco and a Y Combinator W23 graduate, Scanbase raised $2.5 million from Dupe Ventures and Liquid 2 Ventures, achieving $3 million in revenue in 2024 with a 5-person team.\n\nScanbase's API integrates into health apps, telehealth platforms, and employee health programs — when a user takes a photo of their at-home test strip, the API analyzes the image to detect control line and test line presence/intensity, returning a validated result (positive, negative, invalid) with confidence scores. This replaces manual result entry (prone to misinterpretation) and photo review by human staff with automated, consistent computer vision interpretation. The API covers 40+ test types including COVID-19, flu A/B, RSV, pregnancy, and various STD tests.\n\nIn 2025, Scanbase competes in the digital diagnostics and at-home testing technology market with Sight Diagnostics, LumiraDx, and platform-specific solutions built by major diagnostics companies for at-home test result interpretation. The COVID-19 pandemic permanently expanded at-home testing adoption, creating a large installed base of consumers comfortable with lateral flow tests and a growing need for digital result capture and verification in telehealth workflows. The $3M ARR with a 5-person team demonstrates exceptional capital efficiency. The 2025 strategy focuses on expanding the test coverage library, growing integrations with telehealth and employee health platforms, and adding verification workflows for use cases where authenticated test results are needed (insurance claims, return-to-work programs).

Full profile

Manus AI

ChallengerAI & Machine Learning

Autonomous AI Agents

General-purpose autonomous AI agent. $125M+ revenue run rate. Acquired by Meta for $2B+ (Dec 2025). Founded 2022, China/Singapore. MIT Innovators Under 35.

AI VisibilityBeta
Overall Score
B63
Category Rank
#1 of 2
AI Consensus
66%
Trend
up
Per Platform
ChatGPT
66
Perplexity
64
Gemini
54

About

Manus AI is a general-purpose autonomous AI agent developed by Butterfly Effect Pte Ltd, founded in 2022 by Yichao "Peak" Ji and Xiao Hong. Relocated from China to Singapore (mid-2025). Launched March 6, 2025, autonomously handling complex tasks like market research, coding, data analysis, and content creation without human intervention.

Full profile

AI Visibility Head-to-Head

20
Overall Score
63
#1030
Category Rank
#1
58
AI Consensus
66
up
Trend
up
20
ChatGPT
66
20
Perplexity
64
12
Gemini
54
31
Claude
69
25
Grok
64

Capabilities & Ecosystem

Capabilities

Only Manus AI
Autonomous AI Agents

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.